Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYCS0B)

• Drug Name: ALTENUSIN Drug Info
• Synonyms: AC1L4N6W; AC1Q68NU; SCHEMBL16971034; 4',5'-dihydroxy-5-methoxy-2'-methylbiphenyl-2-carboperoxoic acid; ACM31186126; J-018273; 2-(4,5-dihydroxy-2-methylphenyl)-4-methoxybenzenecarboperoxoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6918469
  ChEBI ID: CHEBI:141340
  CAS Number: CAS 31186-12-6
  TTD Drug ID: DMYCS0B

Molecule-Related Drug Atlas

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[4]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[4]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[5]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[6]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[7]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[8]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[9]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[9]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[9]

Drug(s) Affected By DNA topoisomerase 2-alpha (TOP2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[10]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[11]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[12]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[13]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[14]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[15]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[16]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
DNA topoisomerase 2-alpha (TOP2A)	OT6LPS08	TOP2A_HUMAN	Gene/Protein Processing	[2]

References

• [1] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [2] Dual effectiveness of Alternaria but not Fusarium mycotoxins against human topoisomerase II and bacterial gyrase. Arch Toxicol. 2017 Apr;91(4):2007-2016. doi: 10.1007/s00204-016-1855-z. Epub 2016 Sep 28.
• [3] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Prelude Therapeutics.
• [6] Clinical pipeline report, company report or official report of AbbVie.
• [7] MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
• [8] Clinical pipeline report, company report or official report of Amgen.
• [9] Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
• [10] Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res. 2001 Oct;92(10):1133-7. doi: 10.1111/j.1349-7006.2001.tb01069.x.
• [11] HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase II and . Chem Res Toxicol. 2018 Feb 19;31(2):137-144. doi: 10.1021/acs.chemrestox.7b00302. Epub 2018 Jan 8.
• [12] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [13] Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry. 2011 Apr 19;50(15):3240-9. doi: 10.1021/bi200094z. Epub 2011 Mar 28.
• [14] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [15] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [16] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [17] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [18] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [19] Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1552-6. doi: 10.1111/j.1525-1438.2006.00626.x.